The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
Belal Firwana
No relevant relationships to disclose
Maria Diab
No relevant relationships to disclose
Mohamad Bassam Sonbol
No relevant relationships to disclose
Ibraheem Yousef
No relevant relationships to disclose
Rim Hasan
No relevant relationships to disclose
Shahzad Raza
No relevant relationships to disclose
Donald C. Doll
No relevant relationships to disclose